Central Blood Pressure and Variability Evaluation
Key facts
- Who runs it
- Imperial College Healthcare NHS Trust
- Where
- United Kingdom2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 137 people enrolled
- Started
- 7 Jun 2022
- Ended
- 30 Jun 2024
- Type of study
- Observational
- Record updated
- 31 January 2025
Who can take part
- Age
- 55 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Willing and able to give written informed consent
- infrarenal aneurysms of ≥3cm in size (to include AAA ≥5.5cm in those not proceeding to surgery)
Who cannot take part
- participation in another trial of an investigational product or device within the previous 30 days
- persistent cardiac arrhythmia
- age<55
- any clinically significant medical condition which, in the opinion of the investigator, may interfere with the study results and/or reduce life expectancy to < 2 years
- Patient's with a known genetic aetiology of their AAA
- known bilateral proximal upper extremity obstructive lesions
- those unable to give informed consent
- those too frail to travel for four monthly surveillance
- unable or unwilling to comply with the requirements of the study, in the opinion of the investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Background: A sub-study of the AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) trial indicated a statistically significant association between central blood pressure (BP) variability and abdominal aortic aneurysm (AAA) growth. The role of anti-hypertensive adherence has not been explored in the context of AAA growth.
Read full original descriptionShow less
Objective: To confirm whether higher central BP variability is associated with higher AAA growth rates and to examine the effect of medication adherence on AAA growth rates in a prospective longitudinal cohort study.
Methods: Up to 175 patients will be recruited over ten months from two sites with standardised quality control of AAA, BP and antihypertensive non-adherence measurement. Patients (>55 years), with AAAs ≥3cm in diameter (including AAA ≥5.5cm, not proceeding to surgery) will be recruited and undergo AAA ultrasound (US), BP (peripheral and central) and antihypertensive non-adherence measurements every four months (+/- one month) for 24 months. Ambulatory BP variability data will be collected. Data on medication adherence and beliefs around medications will be collected with validated questionnaires.
Analysis: Primarily, the relationship between central diastolic BP visit-to-visit variability and AAA growth (estimated by multilevel modelling) based on US measurements and secondarily the relationship between central diastolic BP variability and time taken to reach the threshold for AAA repair (5.5 cm) or rupture.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Investigation Into the Effects of Central Blood Pressure Variability and Antihypertensive Adherence on the Size and Growth Rate of Abdominal Aortic Aneurysms
- Record updated
- 31 January 2025